| Original language | English (US) |
|---|---|
| Pages (from-to) | 702-703 |
| Number of pages | 2 |
| Journal | Biological psychiatry |
| Volume | 73 |
| Issue number | 8 |
| DOIs |
|
| State | Published - Apr 15 2013 |
Bibliographical note
Funding Information:Dr. Nahas reports receipt of lecture fees from Eli Lilly and Magventure, Inc., and research funding from the National Institute of Mental Health (NIMH); the National Alliance of Research on Schizophrenia and Depression (NARSAD); the Hope for Depression Research Foundation (HDRF); Neuronetics, Inc. (past); Cyberonics, Inc.; Medtronic, Inc.; MECTA; and Pfizer. Dr Nahas has acted as an unpaid consultant for Neuronetics, Inc., and MECTA.
